Company

Technology Excellence in Darmstadt

About us - Zyagnum AG

Zyagnum is a biotechnology company with the goal of making serious diseases visible and thus treatable at the earliest possible stage. We are convinced that many diseases can be treated and cured better the earlier they are detected. Therefore, we believe that the key to curing the major unsolved medical problems of our time lies in early detection diagnostics.

Since 2007, we have been working with our long-established core team and close partners to develop technologies that can detect these common diseases earlier. The result of this intensive development period is our proprietary EDIM® Technology.

With approx. 50 employees at the Darmstadt site as well as numerous close business partners in Germany and abroad, we are now working on the implementation of our ideas for diagnostics.

Technology Excellence
aus Darmstadt

Zyagnum AG

Zyagnum is a biotechnology company with the goal of making serious diseases visible and thus treatable at the earliest possible stage. We are convinced that many diseases can be treated and cured better the earlier they are detected. Therefore, we believe that the key to curing the major unsolved medical problems of our time lies in early detection diagnostics.

Since 2007, we have been working with our long-established core team and close partners to develop technologies that can detect these common diseases earlier. The result of this intensive development period is our proprietary EDIM® Technology.

With more than 30 employees at the Darmstadt site as well as numerous close business partners in Germany and abroad, we are now working on the implementation of our ideas for diagnostics.

A NEW CHAPTER IN DIAGNOSTICS

OUR MISSION

We are convinced that the earliest possible detection of diseases is the prerequisite for the best possible treatments and optimal chances of recovery.

That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention.

Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them.

A NEW CHAPTER IN DIAGNOSTICS

OUR MISSION

We are convinced that the earliest possible detection of diseases is the prerequisite for the best possible treatments and optimal chances of recovery.

That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention.

Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them.

Read more about the innovative EDIM-Technologie

Zyagnum AG

Company- History

Zyagnum AG

Company History

Based on a unique discovery, we aim to usher in a new era of diagnostics.

1995

DISCOVERY TKTL1

Dr. Johannes Coy discovers new universal biomarker at the German Cancer Research Institute (DKFZ)
2007

FOUNDATION OF ZYAGNUM AG

Zyagnum is founded to develop a technology platform and diagnostic test for cancer.
2010

FIRST IN-HOUSE TEST

We test our first cancer test based on TKTL1. We are not yet satisfied with the test accuracy based on only one antibody. We continue to develop and add the additional parameter Apo10 to the test in the following years.
2013

COMBINED SCORE OF APO10 AND TKTL1 PROVIDES BEST DISCRIMINATION

Grimm et al. show in a performance study in BMC Cancer using oral cavity carcinomas, breast cancer and prostate cancer that the combination of Apo10 and TKTL1 leads to the best possible discrimination between cancer patients and healthy individuals. This lays the foundation for the PanTum Detect® test.
2017

DEVELOPMENT COMPLETED

Zyagnum completes development of the unique EDIM® Technology and receives approval for the PanTum Detect® test.
2018 - 2020

PANTUM DETECT®

Signing of pioneering and long-term international collaborations with development and cooperation partners in China, India and Southeast Asia.
2019

PUBLICATION

Chinese publication in “Nature Communications” journal shows: TKTL1 controls cell cycle from cancer cells.
2022

SCREENING STUDY

Publication of a large, prospective screening study at the University Medical Center Hamburg-Eppendorf to investigate the combination of PanTum Detect and subsequent imaging diagnostics (PET/CT and MRI) in more than 5,000 supposedly healthy subjects without symptoms or cancer history.

Zyagnum Management

Ralf Schierl
Founder & CEO

Hendrik Krämer
CFO / Head of Finance & Sales

Anette Ludwig
COO

Dr. Oliver Feyen
CSO (Chief Scientific Officer)